Skip to main content

Table 5 Studies of adjuvant chemotherapy for biliary tract cancer

From: The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection

Referencea

Year

Design

Resection margin

Tumor location

Stage

Arm

No. of patients

Overall survival

Median (months)

5-year rate (%)

P value

Takada [9]

2002

Prospective

R0–R2

GB

II–IV

FM

Observation

69

43

NA

26.0

14.4

0.0367

Murakami [11]

2009

Retrospective

R0, R1

GB/BD/AoV

II

G + S-1

Observation

50

53

NA

57.0

24.0

<0.001

Neoptolemos [13]

2012

Prospective

R0, R1

BD/AoV

I–IV

FL

G

Observation

31

34

31

18.3

19.5

27.2

NA

NA

Kobayashi [12]

2012

Retrospective

R0, R1

BD

II–IV

G

Observation

51

54

NA

46.0

23.0

0.002

Wirasorn [15]

2013

Retrospective

R0, R1

BD

0–IV

AC

Observation

138

125

21.6

13.4

40.1b

29.4b

0.01

Yamanaka [14]

2013

Retrospective

R0

GB/BD/AoV

I–III

G

Observation

40

158

NA

68.0b

68.7b

NS

This present study

 

Retrospective

R0

GB/BD

II–III

F-based

Observation

53

32

NA

52.4

35.6

0.002

  1. GB gallbladder, BD bile duct, AoV ampulla of Vater, FM 5-fluorouracil and mitomycin C, G gemcitabine, FL 5-fluorouracil and leucovorin, AC non-specific adjuvant chemotherapy, F fluoropyrimidine, NA not available, NS non-significant
  2. aThe reference is presented as the first author’s last name followed by the order number of the reference
  3. b3-year survival rate